ArticleTherapeutic innovation & regulatory science2022

U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression.

Eva G Katz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.